about
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsStealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersSafety of Nanoparticles in MedicineNanoparticle Uptake: The Phagocyte ProblemA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Artefactual nanoparticle activation of the inflammasome platform: in vitro evidence with a nano-formed calcium phosphate.Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy.Nanoparticle mediated non-covalent drug deliveryTUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITYApplications of nanomaterials as vaccine adjuvants.Stealth polymeric vesicles via metal-free click coupling.Particulate systems for targeting of macrophages: basic and therapeutic concepts.Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials.Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery.Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.Cubosomes and hexosomes as versatile platforms for drug delivery.Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation.Microfluidic-assisted self-assembly of complex dendritic polyethylene drug delivery nanocapsules.Nanotoxicity: how the body develops a way to reduce the toxicity of carbon nanotubes.Safety of poly (ethylene glycol)-coated perfluorodecalin-filled poly (lactide-co-glycolide) microcapsules following intravenous administration of high amounts in ratsPeptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis.Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities.Size, Shape, and Sequence-Dependent Immunogenicity of RNA Nanoparticles.ZnO Interactions with Biomatrices: Effect of Particle Size on ZnO-Protein Corona.Hemodynamic Effects of Lipid-Based Oxygen Microbubbles via Rapid Intravenous Injection in Rodents.Fc microparticles can modulate the physical extent and magnitude of complement activity.Complement activation turnover on surfaces of nanoparticles.Nanoparticle effect on neutrophil produced myeloperoxidase.Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation.Impact of graphene oxide on the structure and function of important multiple blood components by a dose-dependent pattern.Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials.Influence of spacer length on the cellular uptake of polymeric nanoparticles.Serial multiple crossed immunoelectrophoresis at a microscale: A stamp-sized 2D immunoanalysis of protein C3 activation caused by nanoparticles.A charge-adaptive nanosystem for prolonged and enhanced in vivo antibiotic delivery.Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.Main trends of immune effects triggered by nanomedicines in preclinical studiesReconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer TherapyPolyserotonin Nanoparticles as Multifunctional Materials for Biomedical ApplicationsLower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery
P2860
Q26744352-D35C1505-8859-4CBD-8D19-F64E9CAF8043Q27496024-4D72F01F-8AA4-47AD-A19C-44BCD51E80AFQ28083076-5C05FF91-DAB8-4A96-A5BC-660AFF2AFD77Q28395287-D2EA30E0-1A2F-4E89-9F44-3BE7623FCCEFQ30431343-6BA7EE9E-1C0A-407A-AA5D-D0147992F993Q35637365-DA67D8ED-DBF9-41BC-9346-75EB83D73FE1Q36829233-9A6416A8-81D7-4025-9E42-DDA65D8CB356Q37104463-CDB5633B-692A-4825-B4E3-EAF54E95280CQ37137646-2A0445D3-B4F2-46AC-95E8-D68B86349D3FQ37159697-00D1EBC2-969D-46B8-8522-FAC9ED8419F0Q37281090-27341F41-18B6-4C14-8079-5010E442AF78Q38020769-6B6EA034-1E17-4FEF-BE9A-2127EE372E2EQ38075542-D4E92139-1423-4A06-87A0-C59C60B80195Q38150118-D3359D38-E9E6-4F92-A1AA-D87F242F293AQ38221915-E13EA661-C0BD-4F52-83FE-E8C0A8B452FDQ38664593-1ABF6BF6-4C4B-4FB2-B4BA-96446D072C11Q38991010-B6FBC6A2-6D7C-4E96-9E3E-EDEB4EF93EC1Q39017196-AE0ABCB9-6452-4B32-A9ED-18EE900A2BD7Q39631113-D627D9CC-62FA-4D51-B530-B579F552DEDCQ40473772-40EE7B7C-8231-427E-9FA7-6380693BBE9DQ41860441-36262D75-A443-4EE9-A765-46746C064851Q42356786-7D374A9B-B706-4F99-A52C-7D86D3053CCFQ42592314-C05FDA40-429B-4324-9431-9E90293AF7FBQ47097375-A31F0A34-37D6-4707-85CB-421F6AA38A0AQ47099252-1BC60BBD-03E3-43D8-ACAC-0AF189C4E235Q48163394-E698E875-C28E-43B2-8D1D-FD81671749E3Q48373815-65B9DB58-0C08-431E-9102-1E231DB9FA3EQ49166049-C5A2C968-53D6-4BBE-BB57-16341B335BF4Q49330389-7E8DDBDD-4847-4DFD-91D5-E16AFFB668C9Q50321556-34AEDC29-62C6-45A7-9665-9EB6ACACE8F8Q50459468-7E9F3CC2-F7BA-4BA8-9DA6-792AC0283BF6Q50961996-779804FB-F178-44C3-B9D8-882B4639A9C0Q50971962-11553B4E-F696-4C24-9864-6570B2681CDDQ51657582-EB538E1B-A5A4-4DAC-91FD-5A38085E701BQ53123061-CCC84F97-82DD-496D-9C08-8C8BCC8E89B9Q55146328-26C61AA0-255F-497A-8841-6108F4CDB70BQ57074417-AFE8CA9B-AEA7-4323-9185-EB4F137DA22BQ58122191-3DE83E45-2728-42C9-877D-C4251EB5EA4DQ58466890-136E6441-23E3-40AB-9C0D-8161FD42413FQ58701950-06FD5280-7C17-4CFA-A8F1-42FA212A76FA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Material properties in complement activation.
@en
Material properties in complement activation.
@nl
type
label
Material properties in complement activation.
@en
Material properties in complement activation.
@nl
prefLabel
Material properties in complement activation.
@en
Material properties in complement activation.
@nl
P2093
P1476
Material properties in complement activation.
@en
P2093
A Christy Hunter
Alina J Andersen
Davoud Ahmadvand
Peter P Wibroe
S Moein Moghimi
P304
P356
10.1016/J.ADDR.2011.06.002
P407
P577
2011-06-12T00:00:00Z